🤑 NYSE: NNVC Early Bird Alert with a lot of potential

NEW PICK: NYSE: NNVC The company’s game-changing agents make [NanoViricides, Inc. (NYSE: NNVC)]( one of the most exciting stories to keep an eye on in the biotech space! Greetings All, Covid-19 is the top reason to pay attention to the company you are about to read about, but the recent and alarming outbreak of hepatitis among children also brings attention onto this small-cap biotech company trading on the NYSE that is a global leader in the development of highly effective antiviral therapies. If you haven’t heard about it yet, hundreds of young children around the world have developed severe cases of hepatitis with no obvious cause. It has left doctors baffled as it is important to note that severe hepatitis in children remains rare. As of July 8, [the World Health Organization reported 1,010 probable cases of the liver condition in 35 countries](. On the heels of this mysterious outbreak, NanoViricides, Inc. (NYSE: NNVC) announced earlier this year that it [initiated a program]( to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F). hAd41-F is thought to be strongly associated with the occurrence of severe hepatitis syndrome in some children! The company believes it can successfully develop a drug candidate against hAd41-F relatively quickly if one or more of its existing pipeline candidates or other nanoviricide candidates in its drug candidate library is effective. This is a development to keep a very close eye on… Excitingly (NYSE: NNVC) also announced back in May that it had approximately $16M of current assets. The company thus believes it has sufficient funds for initial human clinical trials of NV-CoV-2! [Image]( That’s the company’s lead coronavirus drug candidate that could become a game changer in fighting the pandemic. The fact that it is expected to enter human clinical trials soon is another reason to have (NYSE: NNVC) at the top of your radar! Trading at right under $2.00, NanoViricides, Inc. (NYSE: NNVC) is a development stage company with breakthrough nanomedicine technology and is developing nanotechnology-based biomimetic anti-viral medicines called “nanoviricides” that could revolutionize the healthcare arena! [Image]( [( NanoViricides, Inc. NYSE: NNVC A New Era in Targeted Anti-Viral Therapeutics. NanoViricides, Inc. (NYSE: NNVC) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Their platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides, Inc. (NYSE: NNVC) is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility! The Company intends to produce its drugs for clinical trials in this facility and has the capability to produce sufficient drugs for about 1,000-5,000 patients in a single batch of production, depending upon the drug and the dosage. This production capacity is anticipated to be sufficient for first-in-human use in the current SARS-CoV-2 pandemic for their anti-coronavirus drug in development, as well as for the anticipated clinical trials of NV-HHV-101 skin cream for the treatment of shingles. The COVID-19 Opportunity It has become clear with the advent of the Omicron sub-variant BA.2.12.1 and other sub-variants that the pandemic is not yet over…. With the evolution of variants, vaccine efficacy has decreased significantly, even with booster shots. The limitations of vaccines and booster shots in combatting a viral pandemic have become abundantly clear through the course of the last two years. The fact that viruses escape vaccines and antibody drugs has also become amply evident. NanoViricides, Inc. (NYSE: NNVC) is pursuing a clinical trial application for its lead drug candidate for the treatment of COVID-19, NV-CoV-2. This drug candidate is designed to act by a novel mechanism of action, that we call "Re-infection Blocker". NV-CoV-2 was found to be a broad-spectrum, pan-coronavirus drug candidate in pre-clinical studies. Highly effective antivirals such as NV-CoV-2 are desperately needed for the world to return to normalcy, as evidenced by the significant interest in antiviral drugs such as remdesivir (Gilead), molnupiravir (Merck), Paxlovid (Pfizer), and a few others in development! Escape of virus due to variants is expected to be highly unlikely because of this broad-spectrum antiviral activity of NV-CoV-2. NV-CoV-2 was also found to be significantly more effective than remdesivir in animal studies of lethal direct lung coronavirus infection that simulates the SARS-CoV-2 disease. Remdesivir is so far the only fully-approved drug for the treatment of SARS-CoV-2 (COVID-19) at present. NV-CoV-2 has been found to be extremely safe and non-mutagenic in GLP and Non-GLP Safety/Toxicology studies. NanoViricides, Inc. (NYSE: NNVC) has also developed Oral Syrup and "Oral Gummies" formulations of NV-CoV-2 for oral administration. The Company has begun cGMP-compliant manufacturing operations for the production of a large batch of the drug substance and the drug products NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies for upcoming anticipated human clinical trials for COVID-19. Clinical trial protocol for evaluation of safety and preliminary evaluation of efficacy upon oral administration of NV-CoV-2 has been defined and agreed with certain consultants already. The Company reports that it is now in the final stages of preparing the documents for submission of a clinical trial application. Oral gummies are expected to be more readily acceptable to children and older patients because of slow dissolution in the mouth and palatability, than oral pills that may be difficult to swallow. NV-CoV-2 has demonstrated good oral bioavailability in animal studies. The Company believes that an effective oral drug to treat COVID-19 remains an unmet medical need given the limitations of available oral drugs! The Company has also developed NV-CoV-2 formulations for injection, infusion and direct lung inhalation using a simple mouthpiece. The inhalation drug formulation is expected to benefit severely ill patients as it enables delivering much higher levels of drug (than infusion or oral dosing) directly to the lung tissue thereby helping to minimize the lung viral load and lung damage, which is expected to lead to rapid recovery of hospitalized patients. The Need to Stop the Hepatitis Outbreak in Children NanoViricides, Inc. (NYSE: NNVC) also recently disclosed that it has begun work on developing an antiviral drug against human Adenovirus-41, Type F (hAd41-F), which is widely believed to be the cause of the growing number of hepatitis cases in children worldwide that have required liver transplants and have reported fatalities. [Image]( It is thought that a combination of prior SARS-CoV-2 exposure or infection, along with a hAd41-F infection may be responsible for this devastating syndrome, although no definitive cause of this hepatitis syndrome has been established. ([( . See also, [(. The Company has already begun development of an antiviral assay for h-Ad41F in its own BSL2 laboratory! The Company plans to first screen its novel nanoviricides that have been effective against different viruses, including adenoviruses. The Company has previously developed a highly effective drug candidate demonstrated in animal studies against adenoviral Epidemic Kerato-Conjunctivitis, which is in its pipeline towards clinical development. (NYSE: NNVC) will remain focused on NV-CoV-2 clinical development as the first priority while it screens for nanoviricides attacking hAd41-F. The Company has also previously completed IND-enabling studies for its drug candidate NV-HHV-101 for the treatment of shingles rash caused by reactivation of the chickenpox virus (aka varicella-zoster virus, VZV). The Company plans on further developing the shingles drug candidate into human clinical trials after clinical trials of their COVID-19 drug candidate. They also intend to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. There is an estimated [one million cases]( of shingles (herpes zoster, HZ) occur in the United States each year. MORE REASONS TO HAVE [NNVC]( ON YOUR RADAR INCLUDE: - The company is led by the renowned inventor of nanoviricides technology, Dr. Anil Diwan, and is managed by a highly effective team who have decades of entrepreneurial, pharmaceutical, and nanomedicine experience. - Strong P&E assets comprise the company’s cGMP-capable manufacturing and R&D facility. - The company’s drug products could significantly change the world if and they contend when hit the market. - Over 15+ years of experience in nanomedicine and antiviral therapy developments. - Fast moving drug candidate developments for the treatment of SARS-CoV-2 in patients. - A strong, diverse, and promising product pipeline that addresses the world’s most infamous and infectious viruses. - The antiviral therapy and nanomedicine market is expected to experience exponential growth in the coming years as more viruses emerge. - The company’s developments are sustainable beyond COVID-19 as their diverse product pipeline targets several markets simultaneously: - The [global HIV drugs marke]( is projected to grow from $30.46 billion in 2021 to $45.58 billion in 2028 at a CAGR of 5.9% in forecast period, 2021-2028. - The [global influenza medication market]( stood at USD 889.2 million in 2018 and is projected to reach USD 993.7 million by 2026, exhibiting a CAGR of 2.2% during the forecast period. - The [shingles treatment marke]( is expected to witness a high growth over the forecast period owing to the increasing prevalence of shingles .The global Shingles Treatments market is valued at million USD in 2017 and is expected to reach million USD by the end of 2023, growing at a CAGR of between 2017 and 2023. As COVID-19 continues to spread across the globe, increased demand for nanomedicine has led to the strong growth of the global nanomedicine market. The Nanomedicine Market was valued at $111.9 Billion in 2016, and is anticipated to reach $261.0 Billion by 2023, according to [AlliedMarketResearch.]( But it’s the fact that the company’s programs address large markets within the antiviral space that could result in [treatment-transformations]( and market size explosions. NanoViricides, Inc. (NYSE: NNVC) is quickly proving to be a new hero in the biotech arena and looks like one of the most promising growth stories hiding on the NYSE! The company’s unique mechanism could redefine the medical landscape when it comes to viruses so start your research right away! Copyright 2022 © PTE.la is owned and operated by CareBear Marketing Group LLC. [Disclaimer and Privacy]( more Information please contact Support@pte.la Company Address: 26 Downing Street, Newark NJ 07105. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. CareBear Marketing Group, its managers, its employees, affiliates and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses. You received this message as part of your subscription to PTE. PTE is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “PTE” refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and the number of shares here. We do not own any shares in NNVC. We have been compensated Seventy-Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third party Open Market Media Group LLC for a 3 Day Marketing Program regarding NNVC with a start date of 8/02/2022 to 8/04/2022. PTE’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, PTE often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](